SG11202103092VA - Fgfr4 inhibitor and use thereof - Google Patents
Fgfr4 inhibitor and use thereofInfo
- Publication number
- SG11202103092VA SG11202103092VA SG11202103092VA SG11202103092VA SG11202103092VA SG 11202103092V A SG11202103092V A SG 11202103092VA SG 11202103092V A SG11202103092V A SG 11202103092VA SG 11202103092V A SG11202103092V A SG 11202103092VA SG 11202103092V A SG11202103092V A SG 11202103092VA
- Authority
- SG
- Singapore
- Prior art keywords
- fgfr4 inhibitor
- fgfr4
- inhibitor
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
- C07D487/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains four or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
- C07D471/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
- C07D491/147—Ortho-condensed systems the condensed system containing one ring with oxygen as ring hetero atom and two rings with nitrogen as ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains three hetero rings
- C07D495/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/12—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains three hetero rings
- C07D513/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN2018107902 | 2018-09-27 | ||
PCT/CN2019/108298 WO2020063788A1 (zh) | 2018-09-27 | 2019-09-26 | Fgfr4抑制剂及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11202103092VA true SG11202103092VA (en) | 2021-04-29 |
Family
ID=69953396
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11202103092VA SG11202103092VA (en) | 2018-09-27 | 2019-09-26 | Fgfr4 inhibitor and use thereof |
Country Status (15)
Country | Link |
---|---|
US (1) | US20220002307A1 (ja) |
EP (1) | EP3848377A4 (ja) |
JP (1) | JP7446287B2 (ja) |
KR (1) | KR20210066839A (ja) |
CN (1) | CN112771049B (ja) |
AU (1) | AU2019348120A1 (ja) |
BR (1) | BR112021005750A2 (ja) |
CA (1) | CA3114147A1 (ja) |
EA (1) | EA202190885A1 (ja) |
IL (1) | IL281798A (ja) |
MX (1) | MX2021003531A (ja) |
SG (1) | SG11202103092VA (ja) |
TW (1) | TWI822868B (ja) |
WO (1) | WO2020063788A1 (ja) |
ZA (1) | ZA202102192B (ja) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220159457A (ko) * | 2020-03-27 | 2022-12-02 | 베타 파머수티컬 컴퍼니 리미티드 | Fgfr4 억제제의 염 형태, 결정 형태 및 그 용도 |
JP2022108517A (ja) * | 2021-01-13 | 2022-07-26 | 地方独立行政法人東京都健康長寿医療センター | 医薬組成物 |
US20240140962A1 (en) * | 2021-02-08 | 2024-05-02 | Medshine Discovery Inc. | 5,6-dihydrothieno[3,4-h]quinazoline compound |
CN114907350B (zh) * | 2021-02-10 | 2023-12-29 | 上海凌达生物医药有限公司 | 一类含氮稠环类化合物、制备方法和用途 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050070554A1 (en) | 2003-08-27 | 2005-03-31 | Amgen Inc. | Substituted heterocyclic compounds and methods of use |
JP5739820B2 (ja) | 2008-12-30 | 2015-06-24 | アークル インコーポレイテッド | 置換5,6−ジヒドロ−6−フェニルベンゾ[f]イソキノリン−2−アミン化合物 |
TWI532742B (zh) * | 2011-02-28 | 2016-05-11 | 艾伯維有限公司 | 激酶之三環抑制劑 |
CN104271576A (zh) * | 2012-02-23 | 2015-01-07 | 艾伯维公司 | 激酶的吡啶并嘧啶酮抑制剂 |
ES2924111T3 (es) | 2013-10-25 | 2022-10-04 | Blueprint Medicines Corp | Inhibidores del receptor del factor de crecimiento de fibroblastos |
GB201322602D0 (en) | 2013-12-19 | 2014-02-05 | Almac Discovery Ltd | Pharmaceutical compounds |
KR20180002053A (ko) * | 2016-06-28 | 2018-01-05 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
WO2018004258A1 (ko) * | 2016-06-28 | 2018-01-04 | 한미약품 주식회사 | 신규한 헤테로시클릭 유도체 화합물 및 이의 용도 |
AU2017359844B2 (en) | 2016-11-16 | 2021-09-30 | Impact Therapeutics (Shanghai), Inc | 8,9-dihydroimidazole[1,2-a]pyrimido[5,4-e]pyrimidine-5(6H)-ketone compound |
TWI741155B (zh) * | 2017-02-27 | 2021-10-01 | 大陸商貝達藥業股份有限公司 | Fgfr抑制劑及其應用 |
-
2019
- 2019-09-26 MX MX2021003531A patent/MX2021003531A/es unknown
- 2019-09-26 BR BR112021005750-1A patent/BR112021005750A2/pt unknown
- 2019-09-26 EA EA202190885A patent/EA202190885A1/ru unknown
- 2019-09-26 EP EP19867204.0A patent/EP3848377A4/en active Pending
- 2019-09-26 JP JP2021517318A patent/JP7446287B2/ja active Active
- 2019-09-26 SG SG11202103092VA patent/SG11202103092VA/en unknown
- 2019-09-26 KR KR1020217011210A patent/KR20210066839A/ko not_active Application Discontinuation
- 2019-09-26 WO PCT/CN2019/108298 patent/WO2020063788A1/zh unknown
- 2019-09-26 CN CN201980061921.XA patent/CN112771049B/zh active Active
- 2019-09-26 CA CA3114147A patent/CA3114147A1/en active Pending
- 2019-09-26 AU AU2019348120A patent/AU2019348120A1/en active Pending
- 2019-09-26 US US17/280,309 patent/US20220002307A1/en active Pending
- 2019-09-27 TW TW108135161A patent/TWI822868B/zh active
-
2021
- 2021-03-24 IL IL281798A patent/IL281798A/en unknown
- 2021-03-31 ZA ZA2021/02192A patent/ZA202102192B/en unknown
Also Published As
Publication number | Publication date |
---|---|
BR112021005750A2 (pt) | 2021-06-29 |
WO2020063788A8 (zh) | 2023-03-30 |
AU2019348120A1 (en) | 2021-05-06 |
TWI822868B (zh) | 2023-11-21 |
KR20210066839A (ko) | 2021-06-07 |
CN112771049B (zh) | 2024-01-26 |
CA3114147A1 (en) | 2020-04-02 |
US20220002307A1 (en) | 2022-01-06 |
TW202028211A (zh) | 2020-08-01 |
WO2020063788A1 (zh) | 2020-04-02 |
EP3848377A4 (en) | 2022-06-15 |
JP7446287B2 (ja) | 2024-03-08 |
CN112771049A (zh) | 2021-05-07 |
JP2022502438A (ja) | 2022-01-11 |
ZA202102192B (en) | 2022-06-29 |
IL281798A (en) | 2021-05-31 |
EP3848377A1 (en) | 2021-07-14 |
EA202190885A1 (ru) | 2021-06-25 |
MX2021003531A (es) | 2021-07-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IL272910A (en) | Ectonucleotide pyrophosphate-phosphodiesterase 1 (ENPP-1) inhibitors and their uses | |
ZA202002172B (en) | Pde9 inhibitor and use thereof | |
IL276489A (en) | ATR inhibitor and its application | |
IL282350A (en) | Bernani-RGMC inhibitors and their use | |
EP3572400C0 (en) | EZH2 INHIBITOR AND ITS USE | |
ZA202102192B (en) | Fgfr4 inhibitor and use thereof | |
IL277794A (en) | ATF6 inhibitors and uses thereof | |
SI3621694T1 (sl) | Zaviralci lrrc33 in njihove uporabe | |
IL284514A (en) | Halo-allylamine compounds and their use | |
IL279276A (en) | ERK inhibitor and use thereof | |
IL280644A (en) | Magnesium serine compound and its use | |
IL277749A (en) | Palladianolide compounds and their use | |
IL269836B (en) | Converted N-arylethyl-2-aminoquinoline-4-carboxamides and their use | |
ZA201903845B (en) | Fgfr4 inhibitor and preparation method and use thereof | |
GB201801102D0 (en) | New compounds and uses | |
IL280369A (en) | Myokines and their uses | |
EP4051270A4 (en) | 4-AMINO-IMODAZOCINOLINE COMPOUNDS AND USES THEREOF | |
GB201906914D0 (en) | Substituted naphtahlene diimdes and their use | |
IL269843B (en) | Converted N-arylethyl-2-arylquinoline-4-carboxamides and their use | |
GB201806349D0 (en) | New compounds and uses | |
GB201908884D0 (en) | Inhibitors and use | |
IL283540A (en) | Dock1 inhibitory compound and use thereof | |
GB201813311D0 (en) | Novel compounds and their use | |
HK1253249A1 (zh) | 新的5型磷酸二酯酶抑制劑及其應用 | |
GB201815215D0 (en) | Composition and use |